Baidu
map

2021年11月14日简报:张文宏认为有必要继续实施强大的公共卫生政策;国内3至11岁人群超8439万人接种新冠疫苗,18岁以上学生新冠疫苗接种率超95%;

2021-11-14 MedSci整理 MedSci整理

截至北京时间2021年11月14日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿5363万例,新增410,690例,达到253,639,

截至北京时间2021年11月14日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过2亿5363万例,新增410,690例,达到253,639,963例。累计死亡病例511.0万例,达到5,110,026例。新增死亡为5,772例。康复为229,349,436例,重症和危重症病人达到77,601例;全球新冠确诊病例超过100万例的国家达36个,112个国家病例超10万例。昨日报道:2021年11月13日简报:全球首款吸入式腺病毒载体新冠疫苗克威莎亮相;欧洲多国疫情攀升,北欧多国加强控制

全球本轮疫情开始增速,预计高峰时会日增70万新增病例。

国家卫健委:目前3至11岁人群超8439万人接种新冠疫苗

关于新冠病毒疫苗接种工作,根据我们今年下半年新冠病毒疫苗接种的安排,还有冬季疫情防控工作需要,将继续推进重点人群的疫苗加强免疫和3-11岁人群的新冠病毒疫苗接种工作,对重点人群要实现“应接尽接”。目前,3-11岁人群已经接种了8439.5万人,加强免疫已经接种4944万人,我们将力争在12月底完成3-11岁人群的全程接种工作。同时,指导各地合理安排资源,统筹做好流感等呼吸道疫苗的接种工作,降低呼吸道传染病和新冠肺炎叠加流行的风险。各地也在结合实际情况,创新服务模式,合理设置接种单位,做好恶劣天气下的接种安排,方便群众接种。

张文宏:继续实施强大的公共卫生政策

“全球累计新冠肺炎死亡病例数超过五百万。如果没有全球有效的公共卫生,这个五百万乘以十都是可以预计的。”张文宏教授发表题为《传染病消除:挑战与未来》的演讲时说。

此前张文宏曾表示,未来新冠疫情发展的趋势是群体免疫水平会逐渐升高,“人们要么通过疫苗接种获得免疫,要么通过感染获得免疫。”

张文宏说,从目前情况看,新冠肺炎比以往任何一次呼吸道传染病都要难对付,无论接种的是什么疫苗,无论保护率有多高,即便完成了两针接种,似乎还是不能完全阻挡这个疾病的传播。“但是,以色列已经完成了44%人口的第三针免疫接种,可以看到,以色列的数据跟新加坡、英国截然不同,发病率开始下降,这意味着将来我们还需要在免疫的强化策略上面做得更好。”

“因此,即便疫苗接种达到非常高的水平,还得继续实施一个非常强大的公共卫生政策,建立强大的公共卫生体系,具备强大的预警能力,做到早期发现、动态清零、充分救治。”

全国10.73亿人完成新冠疫苗全程接种

昨天,在国务院联防联控机制召开的新闻发布会上发布数据:截至12日,全国累计报告接种新冠疫苗23.72亿剂次,完成新冠疫苗全程接种人数为10.73亿人。

18岁以上学生新冠疫苗接种率超95%

昨天,在国务院联防联控机制召开新闻发布会上,教育部防控办主任、体育卫生与艺术教育司司长王登峰介绍,目前,全国18岁以上学生新冠疫苗接种率已达95%以上。教育部鼓励所有高校在属地管理的前提下,结合校园防控要求以及课程进展、学习安排情况,自主决定放寒假时间。

美国日增新冠病例再现反弹趋势

据美国约翰斯·霍普金斯大学统计数据,截至美国东部时间11月11日下午6时,全美共报告新冠肺炎确诊46839596例,死亡759602例。过去24小时,美国新增确诊70782例,新增死亡956例。美联社报道称,受德尔塔毒株的影响,美国西部和北部一些州住院病例和确诊病例出现上升,这是今年冬天美国疫情令人担忧的迹象。

德国和荷兰日增新冠确诊病例数创新高

当地时间11月11日,据德国疾病控制和预防机构罗伯特·科赫研究所(RKI)的最新统计数据显示,在过去24小时,德国新增新冠肺炎确诊病例50196例,系疫情暴发以来首次突破5万例,并已连续四天创新高。截至目前,德国累计确诊病例4894250例;累计死亡97198例。

有专家认为,近期德国疫情反弹主要是因为该国某些地区的新冠疫苗接种率偏低,以及接种加强针的进度缓慢。德国知名病毒学家德罗斯滕警告说,若不采取足够的防疫措施,因新冠肺炎死亡的人数可能会再增加10万人。

荷兰国家公共卫生与环境研究所11日公布的数据显示,荷兰24小时内新增确诊病例达到创纪录的16364例,新增入院病例和新增重症病例也较前一天有所增加。

非洲地区累计死亡病例超22万例

据非洲疾控中心数据显示,截至当地时间11月11日,非洲地区累计新冠肺炎确诊病例达8546650例,累计死亡病例220225例。

当地时间11月11日,世卫组织非洲区域办事处在刚果(布)首都布拉柴维尔召开在线记者会。记者会消息称,非洲大陆累计确诊新冠肺炎病例已超过850万,因疫苗接种率不高,非洲大陆患有糖尿病等基础疾病的群体一旦感染新冠病毒,将面临巨大的死亡风险。研究表明,患有糖尿病、艾滋病和高血压的新冠肺炎患者,其死亡率显著高于一般的新冠患者。

另据世卫组织的数据显示,目前非洲仅有6.6%的人口完成了新冠疫苗接种。而在全球,疫苗的平均接种率为40%。根据37个非洲国家的数据,自今年3月起,已给患有基础疾病的人群接种了650万剂新冠疫苗,占所有剂量的14%。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078677, encodeId=bcb320e86779f, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Mar 06 21:05:10 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258115, encodeId=40c9125811569, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260516, encodeId=379712605162a, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374092, encodeId=03cd13e409283, content=<a href='/topic/show?id=5d093663656' target=_blank style='color:#2F92EE;'>#卫生政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36636, encryptionId=5d093663656, topicName=卫生政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070151, encodeId=e6f910e015163, content=预防为主。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1bc5420323, createdName=wanyych, createdTime=Sun Nov 14 14:19:59 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070109, encodeId=455810e01094f, content=希望快点结束哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951a5116951, createdName=14629447m07暂无昵称, createdTime=Sun Nov 14 11:25:40 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070070, encodeId=598a10e007018, content=收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28385710431, createdName=ms8000000632343448, createdTime=Sun Nov 14 09:28:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070057, encodeId=faa010e0057c4, content=受益匪浅,谢谢谢谢谢谢谢谢谢谢谢谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a255398271, createdName=ms4000000375523330, createdTime=Sun Nov 14 08:53:16 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2022-03-06 gous
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078677, encodeId=bcb320e86779f, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Mar 06 21:05:10 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258115, encodeId=40c9125811569, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260516, encodeId=379712605162a, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374092, encodeId=03cd13e409283, content=<a href='/topic/show?id=5d093663656' target=_blank style='color:#2F92EE;'>#卫生政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36636, encryptionId=5d093663656, topicName=卫生政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070151, encodeId=e6f910e015163, content=预防为主。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1bc5420323, createdName=wanyych, createdTime=Sun Nov 14 14:19:59 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070109, encodeId=455810e01094f, content=希望快点结束哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951a5116951, createdName=14629447m07暂无昵称, createdTime=Sun Nov 14 11:25:40 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070070, encodeId=598a10e007018, content=收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28385710431, createdName=ms8000000632343448, createdTime=Sun Nov 14 09:28:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070057, encodeId=faa010e0057c4, content=受益匪浅,谢谢谢谢谢谢谢谢谢谢谢谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a255398271, createdName=ms4000000375523330, createdTime=Sun Nov 14 08:53:16 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078677, encodeId=bcb320e86779f, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Mar 06 21:05:10 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258115, encodeId=40c9125811569, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260516, encodeId=379712605162a, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374092, encodeId=03cd13e409283, content=<a href='/topic/show?id=5d093663656' target=_blank style='color:#2F92EE;'>#卫生政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36636, encryptionId=5d093663656, topicName=卫生政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070151, encodeId=e6f910e015163, content=预防为主。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1bc5420323, createdName=wanyych, createdTime=Sun Nov 14 14:19:59 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070109, encodeId=455810e01094f, content=希望快点结束哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951a5116951, createdName=14629447m07暂无昵称, createdTime=Sun Nov 14 11:25:40 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070070, encodeId=598a10e007018, content=收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28385710431, createdName=ms8000000632343448, createdTime=Sun Nov 14 09:28:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070057, encodeId=faa010e0057c4, content=受益匪浅,谢谢谢谢谢谢谢谢谢谢谢谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a255398271, createdName=ms4000000375523330, createdTime=Sun Nov 14 08:53:16 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-11-15 bioon3
  4. [GetPortalCommentsPageByObjectIdResponse(id=2078677, encodeId=bcb320e86779f, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Mar 06 21:05:10 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258115, encodeId=40c9125811569, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260516, encodeId=379712605162a, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374092, encodeId=03cd13e409283, content=<a href='/topic/show?id=5d093663656' target=_blank style='color:#2F92EE;'>#卫生政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36636, encryptionId=5d093663656, topicName=卫生政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070151, encodeId=e6f910e015163, content=预防为主。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1bc5420323, createdName=wanyych, createdTime=Sun Nov 14 14:19:59 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070109, encodeId=455810e01094f, content=希望快点结束哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951a5116951, createdName=14629447m07暂无昵称, createdTime=Sun Nov 14 11:25:40 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070070, encodeId=598a10e007018, content=收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28385710431, createdName=ms8000000632343448, createdTime=Sun Nov 14 09:28:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070057, encodeId=faa010e0057c4, content=受益匪浅,谢谢谢谢谢谢谢谢谢谢谢谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a255398271, createdName=ms4000000375523330, createdTime=Sun Nov 14 08:53:16 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2078677, encodeId=bcb320e86779f, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Mar 06 21:05:10 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258115, encodeId=40c9125811569, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260516, encodeId=379712605162a, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374092, encodeId=03cd13e409283, content=<a href='/topic/show?id=5d093663656' target=_blank style='color:#2F92EE;'>#卫生政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36636, encryptionId=5d093663656, topicName=卫生政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070151, encodeId=e6f910e015163, content=预防为主。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1bc5420323, createdName=wanyych, createdTime=Sun Nov 14 14:19:59 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070109, encodeId=455810e01094f, content=希望快点结束哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951a5116951, createdName=14629447m07暂无昵称, createdTime=Sun Nov 14 11:25:40 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070070, encodeId=598a10e007018, content=收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28385710431, createdName=ms8000000632343448, createdTime=Sun Nov 14 09:28:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070057, encodeId=faa010e0057c4, content=受益匪浅,谢谢谢谢谢谢谢谢谢谢谢谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a255398271, createdName=ms4000000375523330, createdTime=Sun Nov 14 08:53:16 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-11-14 wanyych

    预防为主。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2078677, encodeId=bcb320e86779f, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Mar 06 21:05:10 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258115, encodeId=40c9125811569, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260516, encodeId=379712605162a, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374092, encodeId=03cd13e409283, content=<a href='/topic/show?id=5d093663656' target=_blank style='color:#2F92EE;'>#卫生政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36636, encryptionId=5d093663656, topicName=卫生政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070151, encodeId=e6f910e015163, content=预防为主。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1bc5420323, createdName=wanyych, createdTime=Sun Nov 14 14:19:59 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070109, encodeId=455810e01094f, content=希望快点结束哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951a5116951, createdName=14629447m07暂无昵称, createdTime=Sun Nov 14 11:25:40 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070070, encodeId=598a10e007018, content=收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28385710431, createdName=ms8000000632343448, createdTime=Sun Nov 14 09:28:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070057, encodeId=faa010e0057c4, content=受益匪浅,谢谢谢谢谢谢谢谢谢谢谢谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a255398271, createdName=ms4000000375523330, createdTime=Sun Nov 14 08:53:16 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-11-14 14629447m07暂无昵称

    希望快点结束哇

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2078677, encodeId=bcb320e86779f, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Mar 06 21:05:10 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258115, encodeId=40c9125811569, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260516, encodeId=379712605162a, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374092, encodeId=03cd13e409283, content=<a href='/topic/show?id=5d093663656' target=_blank style='color:#2F92EE;'>#卫生政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36636, encryptionId=5d093663656, topicName=卫生政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070151, encodeId=e6f910e015163, content=预防为主。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1bc5420323, createdName=wanyych, createdTime=Sun Nov 14 14:19:59 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070109, encodeId=455810e01094f, content=希望快点结束哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951a5116951, createdName=14629447m07暂无昵称, createdTime=Sun Nov 14 11:25:40 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070070, encodeId=598a10e007018, content=收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28385710431, createdName=ms8000000632343448, createdTime=Sun Nov 14 09:28:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070057, encodeId=faa010e0057c4, content=受益匪浅,谢谢谢谢谢谢谢谢谢谢谢谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a255398271, createdName=ms4000000375523330, createdTime=Sun Nov 14 08:53:16 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-11-14 ms8000000632343448

    收益

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2078677, encodeId=bcb320e86779f, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Mar 06 21:05:10 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258115, encodeId=40c9125811569, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260516, encodeId=379712605162a, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374092, encodeId=03cd13e409283, content=<a href='/topic/show?id=5d093663656' target=_blank style='color:#2F92EE;'>#卫生政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36636, encryptionId=5d093663656, topicName=卫生政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Mon Nov 15 22:05:10 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070151, encodeId=e6f910e015163, content=预防为主。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1bc5420323, createdName=wanyych, createdTime=Sun Nov 14 14:19:59 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070109, encodeId=455810e01094f, content=希望快点结束哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951a5116951, createdName=14629447m07暂无昵称, createdTime=Sun Nov 14 11:25:40 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070070, encodeId=598a10e007018, content=收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28385710431, createdName=ms8000000632343448, createdTime=Sun Nov 14 09:28:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070057, encodeId=faa010e0057c4, content=受益匪浅,谢谢谢谢谢谢谢谢谢谢谢谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a255398271, createdName=ms4000000375523330, createdTime=Sun Nov 14 08:53:16 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-11-14 ms4000000375523330

    受益匪浅,谢谢谢谢谢谢谢谢谢谢谢谢谢谢谢

    0

相关资讯

2021年11月7日简报:全球新冠重症人数降至一年来很低值;国内10.72亿人完成新冠疫苗全程接种,其中3-11岁儿童接种新冠疫苗超353万剂次;新冠口服治疗药物可能会引入国内

截至北京时间2021年11月7日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿5025万例,新增412,535例,达到250,250,7

2021年11月5日简报:本土疫情涉及到20个省份;英国成为批准默克新冠特效药的国家;国产乐复能也可能是新冠特效药之一

截至北京时间2021年11月5日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿4929万例,新增493,290例,达到249,294,9

2021年11月12日简报:钟南山呼吁接种第三针;新冠废物影响海洋生态;欧洲疫情上升明显,德国日新增超5万例;

截至北京时间2021年11月12日8时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿5261万例,新增493,795例,达到252,618,

到底哪个新冠疫苗更值得信赖?结果令人大吃一惊

论文是知识的载体,经过同行评议的论文更是数据质量经过判决的准确信息。论文和数据,也是几乎所有专家委员会支持或者否定疫苗的依据。

Nat Med:接种新冠疫苗是否会增加神经系统并发症风险?

研究人员估计每1000万接受ChAdOx1nCoV-19的人中有38例增加的吉兰-巴雷综合征病例,而在SARS-CoV-2检测阳性后,每1000万人中有145例增加的病例。

Baidu
map
Baidu
map
Baidu
map